Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
156.87
-0.95 (-0.60%)
At close: Jan 30, 2026, 4:00 PM EST
157.00
+0.13 (0.08%)
After-hours: Jan 30, 2026, 7:59 PM EST
Insmed Revenue
Insmed had revenue of $142.34M in the quarter ending September 30, 2025, with 52.36% growth. This brings the company's revenue in the last twelve months to $447.02M, up 30.34% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$447.02M
Revenue Growth
+30.34%
P/S Ratio
66.80
Revenue / Employee
$351,709
Employees
1,271
Market Cap
33.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | 136.47M | 126.63M | 1,287.56% |
| Dec 31, 2018 | 9.84M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 11.50M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 4.42M | -2.50M | -36.18% |
| Dec 31, 2010 | 6.92M | -3.45M | -33.28% |
| Dec 31, 2009 | 10.37M | -1.33M | -11.33% |
| Dec 31, 2008 | 11.70M | 4.12M | 54.32% |
| Dec 31, 2007 | 7.58M | 6.56M | 639.61% |
| Dec 31, 2006 | 1.03M | 894.00K | 682.44% |
| Dec 31, 2005 | 131.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 4.97B |
| Incyte | 4.81B |
| Genmab | 3.85B |
| BioNTech SE | 3.70B |
| argenx SE | 3.68B |
| Alnylam Pharmaceuticals | 3.21B |
| Royalty Pharma | 2.35B |
| Moderna | 2.23B |
INSM News
- 3 days ago - Artisan Global Opportunities Fund Q4 2025 Portfolio Update - Seeking Alpha
- 4 days ago - Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress - PRNewsWire
- 9 days ago - Artisan Small Cap Fund Q4 2025 Portfolio Activity - Seeking Alpha
- 13 days ago - Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity - Seeking Alpha
- 20 days ago - Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 23 days ago - Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances - Benzinga
- 23 days ago - Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 4 weeks ago - Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire